Jiangsu Walvax Biotech Co.
Division of Yunnan Walvax Biotech Co. Ltd.
Latest From Jiangsu Walvax Biotech Co.
With four new drug approvals notched under its belt in four months, GlaxoSmithKline had several potential growth drivers to highlight during its third quarter earnings call, helping to deflect attention away from the bribery scandal in China.
With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.